Agentix
Agentix, a biopharmaceutical firm, develops health solutions and modulates the ECS for therapeutic targets, based in California.
Founded
2013Agentix, a biopharmaceutical firm, develops health solutions and modulates the ECS for therapeutic targets, based in California.
Agentix, founded in California, is a clinical-stage biopharmaceutical company dedicated to developing innovative health solutions targeting the endocannabinoid system (ECS). Their mission is to address metabolic diseases such as Type 2 Diabetes Mellitus, Chronic Obesity, and Non-alcoholic Fatty Liver Disease through a suite of novel, science-driven biopharmaceuticals. By focusing on synthetic agonists, inverse agonists, and antagonists that modulate ECS, Agentix aims to offer therapeutic solutions with greater market exclusivity.
Notable figures associated with Agentix include experienced scientists and industry veterans who drive its research and development efforts. The company has attracted significant investment from stakeholders interested in pioneering treatments for metabolic diseases. Key achievements include progressing to clinical-stage trials and developing a robust pipeline of ECS-targeting therapeutics. Agentix's impact lies in its potential to revolutionize the treatment of metabolic disorders, offering new hope to patients worldwide.
Companies similar to Agentix include Equator Therapeutics, AgoneX Biopharmaceuticals, KinDex Pharmaceuticals and Demetrix.
Agentix was founded in 2013.
Agentix's headquarters is located in Dana Point, CA, US.
Agentix's most recent funding round was for $688.3k (USD) in February 2021.
As of Feb 10, 2021, Agentix has disclosed funding of $808.3k (USD). Undisclosed round amounts are excluded.
Agentix has 7 employees as of Feb 5, 2024.
Demetrix
demetrix.com
